N-truncated amyloid β (Aβ) 4-42 forms stable aggregates and induces acute and long-lasting behavioral deficits
Open accessThe DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
Abstract
N-truncated Aβ4-42 is highly abundant in Alzheimer disease (AD) brain and was the first Aβ peptide discovered in AD plaques. However, a possible role in AD aetiology has largely been neglected. In the present report, we demonstrate that Aβ4-42 rapidly forms aggregates possessing a high aggregation propensity in terms of monomer consumption and oligomer formation. Short-term treatment of primary cortical neurons indicated that Aβ4-42 is as toxic as pyroglutamate Aβ3-42 and Aβ1-42. In line with these findings, treatment of wildtype mice using intraventricular Aβ injection induced significant working memory deficits with Aβ4-42, pyroglutamate Aβ3-42 and Aβ1-42. Transgenic mice expressing Aβ4-42 (Tg4-42 transgenic line) developed a massive CA1 pyramidal neuron loss in the hippocampus. The hippocampus-specific expression of Aβ4-42 correlates well with age-dependent spatial reference memory deficits assessed by the Morris water maze test. Our findings indicate that N-truncated Aβ4-42 triggers acute and long-lasting behavioral deficits comparable to AD typical memory dysfunction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As Aβ4–42 is predominantly expressed in the CA1 region in Tg4–42hom mice [21], hippocampal mRNA extracts were used for the analysis of both transgenes.”
From Characterization of a Mouse Model of Alzheimer’s Disease Expressing Aβ4-42 and Human Mutant Tau (2021) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The Tg4–42 mouse model used in the present study primarily shows an intraneuronal accumulation of Aβ peptides, in particular in CA1 hippocampal neurons, and does not form overt extracellular plaques [21].”
From Characterization of a Mouse Model of Alzheimer’s Disease Expressing Aβ4-42 and Human Mutant Tau (2021) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Spatial reference memory in 5xFAD Lrp1 BE -/-mice and 5xFAD Lrp1 BE fl/fl control mice was assessed using the Morris water maze (40) by a blinded investigator as described previously (41).”
From Endothelial LRP1 transports amyloid-β1–42 across the blood-brain barrier (2015) · cites this paper as [41]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“We have recently generated a transgenic mouse model (Tg4–42) that overexpresses Aβ4–42 peptides under the control of the murine neuron-specific Thy1-promoter [21].”
From Characterization of a Mouse Model of Alzheimer’s Disease Expressing Aβ4-42 and Human Mutant Tau (2021) · cites this paper as [21]
The cited source says what the claim attributes to it.
In the citing paper
“In brief, the human Aβ4-42 sequence is fused to the signal peptide sequence of the thyrotropin-releasing hormone and the expression is under the control of the Thy1 promoter.”
From Characterization of a Mouse Model of Alzheimer’s Disease Expressing Aβ4-42 and Human Mutant Tau (2021) · cites this paper as [21]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769
RetractedPfaffl, M. W. (2002) · Nucleic Acids Research · doi:10.1093/nar/30.9.e36 · Cited by 7,376
Developments of a water-maze procedure for studying spatial learning in the rat
Morris, R. (1984) · Journal of Neuroscience Methods · doi:10.1016/0165-0270(84)90007-4 · Cited by 7,180
Alzheimer's Disease: Genes, Proteins, and Therapy
Selkoe, D. J. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.2.741 · Cited by 6,063
Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide
Haass, C., & Selkoe, D. J. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2101 · Cited by 4,744 · cited 2×
“1 3 There is increasing evidence that the primary insult in AD is caused by oligomeric species derived from fulllength Aβ1-42 impairing synaptic functions [14, 67].”
BackgroundMorris water maze: procedures for assessing spatial and related forms of learning and memory
Vorhees, C. V., & Williams, M. T. (2006) · Nature Protocols · doi:10.1038/nprot.2006.116 · Cited by 4,629
Amyloid plaque core protein in Alzheimer disease and Down syndrome.
Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L., & Beyreuther, K. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.12.4245 · Cited by 4,431
Shankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1782 · Cited by 3,685
Oakley, H., Cole, S. L., Logan, S., Maus, E., Shao, P., Craft, J., Guillozet-Bongaarts, A., Ohno, M., Disterhoft, J., Van Eldik, L., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.1202-06.2006 · Cited by 3,530 · cited 6×
“In 5XFAD, another mouse model expressing mutant APP and PS1 [42], a heterogeneous mixture of full-length, N-truncated and modified Aβ peptides, including Aβ4-42, were found [70].”
BackgroundInfluentialDiffusible, nonfibrillar ligands derived from Aβ 1–42 are potent central nervous system neurotoxins
Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6448 · Cited by 3,506 · cited 1×
“Small, soluble Aβ1-42 oligomers ranging in size from dimers to dodecamers have been found as key drivers of neurotoxicity in vitro and in vivo [6, 28, 30, 43, 61, 71].”
BackgroundWest, M. J., Slomianka, L., & Gundersen, H. J. G. (1991) · The Anatomical Record · doi:10.1002/ar.1092310411 · Cited by 2,994
The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes
Benilova, I., Karran, E., & De Strooper, B. (2012) · Nature Neuroscience · doi:10.1038/nn.3028 · Cited by 1,962 · cited 4×
“In addition to the numerous variants of Aβ1-42 oligomers currently being discussed [3], there is substantial evidence that N-terminal truncated peptides play a key role in AD [20].”
BackgroundInfluentialIwatsubo, T., Odaka, A., Suzuki, N., Mizusawa, H., Nukina, N., & Ihara, Y. (1994) · Neuron · doi:10.1016/0896-6273(94)90458-8 · Cited by 1,774
Shankar, G. M., Bloodgood, B. L., Townsend, M., Walsh, D. M., Selkoe, D. J., & Sabatini, B. L. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.4970-06.2007 · Cited by 1,592
Kawarabayashi, T., Younkin, L. H., Saido, T. C., Shoji, M., Ashe, K. H., & Younkin, S. G. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-02-00372.2001 · Cited by 1,053 · cited 1×
“In Tg2576 mice, truncated and modified Aβ isoforms do not appear before 1 year of age and comprise approximately 5 % of total Aβ [22].”
BackgroundSpatial memory, recognition memory, and the hippocampus
Broadbent, N. J., Squire, L. R., & Clark, R. E. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0406344101 · Cited by 985 · cited 1×
“[5] examined the relationship between hippocampal lesion size and spatial memory in rats.”
BackgroundSpatial learning with a minislab in the dorsal hippocampus.
Moser, M. B., Moser, E. I., Forrest, E., Andersen, P., & Morris, R. G. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.21.9697 · Cited by 898
The cell biology of β-amyloid precursor protein and presenilin in Alzheimer's disease
Selkoe, D. (1998) · Trends in Cell Biology · doi:10.1016/s0962-8924(98)01363-4 · Cited by 862
Roher, A. E., Lowenson, J. D., Clarke, S., Wolkow, C., Wang, R., Cotter, R. J., Reardon, I. M., Zürcher-Neely, H. A., Heinrikson, R. L., & Ball, M. J. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)53661-9 · Cited by 799
Structure–neurotoxicity relationships of amyloid β-protein oligomers
Ono, K., Condron, M. M., & Teplow, D. B. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905127106 · Cited by 770
Jawhar, S., Trawicka, A., Jenneckens, C., Bayer, T. A., & Wirths, O. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.05.027 · Cited by 623
Self-citationAmyloid β-Protein Assembly and Alzheimer Disease
Roychaudhuri, R., Yang, M., Hoshi, M. M., & Teplow, D. B. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.r800036200 · Cited by 615
Saido, T. C., Iwatsubo, T., Mann, D. M. A., Shimada, H., Ihara, Y., & Kawashima, S. (1995) · Neuron · doi:10.1016/0896-6273(95)90301-1 · Cited by 587 · cited 1×
“[54] showed by immunohistochemical and biochemical means that Aβpe3 is present in equivalent or larger amounts than full-length Aβ in senile plaques.”
Dong, J., Atwood, C. S., Anderson, V. E., Siedlak, S. L., Smith, M. A., Perry, G., & Carey, P. R. (2003) · Biochemistry · doi:10.1021/bi0272151 · Cited by 562
Aβ toxicity in Alzheimer’s disease: globular oligomers (ADDLs) as new vaccine and drug targets
Klein, W. L. (2002) · Neurochemistry International · doi:10.1016/s0197-0186(02)00050-5 · Cited by 545
Solution Structures of β Peptide and Its Constituent Fragments: Relation to Amyloid Deposition
Barrow, C. J., & Zagorski, M. G. (1991) · Science · doi:10.1126/science.1853202 · Cited by 537
Sarter, M., Bodewitz, G., & Stephens, D. N. (1988) · Psychopharmacology · doi:10.1007/bf00212843 · Cited by 530
Miller, D. L., Papayannopoulos, I. A., Styles, J., Bobin, S. A., Lin, Y. Y., Biemann, K., & Iqbal, K. (1993) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1993.1112 · Cited by 510
Mass spectrometry of purified amyloid beta protein in Alzheimer's disease.
Mori, H., Takio, K., Ogawara, M., & Selkoe, D. J. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)41896-0 · Cited by 483
Näslund, J., Schierhorn, A., Hellman, U., Lannfelt, L., Roses, A. D., Tjernberg, L. O., Silberring, J., Gandy, S. E., Winblad, B., & Greengard, P. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.18.8378 · Cited by 468
Deleterious Effects of Amyloid β Oligomers Acting as an Extracellular Scaffold for mGluR5
Renner, M., Lacor, P. N., Velasco, P. T., Xu, J., Contractor, A., Klein, W. L., & Triller, A. (2010) · Neuron · doi:10.1016/j.neuron.2010.04.029 · Cited by 468 · cited 1×
“recently, it was demonstrated that Aβ1-42 oligomers trigger cell surface receptor clustering near or within synapses, leading to mglur5 dysfunction [49].”
BackgroundCasas, C., Sergeant, N., Itier, J.-M., Blanchard, V., Wirths, O., van der Kolk, N., Vingtdeux, V., van de Steeg, E., Ret, G., Canton, T., et al. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63388-3 · Cited by 400
Self-citationCommon structure and toxic function of amyloid oligomers implies a common mechanism of pathogenesis
Glabe, C. G., & Kayed, R. (2006) · Neurology · doi:10.1212/01.wnl.0000192103.24796.42 · Cited by 367
Differences Between Vascular and Plaque Core Amyloid in Alzheimer's Disease
Prelli, F., Castano, E., Glenner, G. G., & Frangione, B. (1988) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1988.tb01087.x · Cited by 351
Portelius, E., Bogdanovic, N., Gustavsson, M. K., Volkmann, I., Brinkmalm, G., Zetterberg, H., Winblad, B., & Blennow, K. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0690-1 · Cited by 348
Monoclonal antibodies that target pathological assemblies of Aβ
Lambert, M. P., Velasco, P. T., Chang, L., Viola, K. L., Fernandez, S., Lacor, P. N., Khuon, D., Gong, Y., Bigio, E. H., Shaw, P., et al. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04157.x · Cited by 314 · cited 1×
“These include soluble Aβ1-42 dimers, trimers, tetramers and other variants, which have been demonstrated to be neuro- and/or synaptotoxic using cell or tissue culture models [29, 30, 43, 60, 61].”
BackgroundAmino-terminal Deletions Enhance Aggregation of β-Amyloid Peptides in Vitro
Pike, C. J., Overman, M. J., & Cotman, C. W. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.41.23895 · Cited by 302
Maeda, J., Ji, B., Irie, T., Tomiyama, T., Maruyama, M., Okauchi, T., Staufenbiel, M., Iwata, N., Ono, M., Saido, T. C., et al. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.0673-07.2007 · Cited by 300
Schmitz, C., Rutten, B. P. F., Pielen, A., Schäfer, S., Wirths, O., Tremp, G., Czech, C., Blanchard, V., Multhaup, G., Rezaie, P., et al. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63235-x · Cited by 281 · cited 1×
“Stereological analysis was performed as previously described [57].”
MethodSelf-citationKuo, Y.-M., Kokjohn, T. A., Beach, T. G., Sue, L. I., Brune, D., Lopez, J. C., Kalback, W. M., Abramowski, D., Sturchler-Pierrat, C., Staufenbiel, M., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m007859200 · Cited by 246
Kumar, S., Rezaei‐Ghaleh, N., Terwel, D., Thal, D. R., Richard, M., Hoch, M., Mc Donald, J. M., Wüllner, U., Glebov, K., Heneka, M. T., et al. (2011) · The EMBO Journal · doi:10.1038/emboj.2011.138 · Cited by 219
Self-citationPyroglutamate Amyloid-β (Aβ): A Hatchet Man in Alzheimer Disease
Jawhar, S., Wirths, O., & Bayer, T. A. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.r111.288308 · Cited by 218
Self-citationHarigaya, Y., Saido, T. C., Eckman, C. B., Prada, C.-M., Shoji, M., & Younkin, S. G. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.3490 · Cited by 202 · cited 2×
“This was further confirmed by the finding that AβpE3-42 constituted 25 % of the total Aβx-42 in plaques of AD brains [15].”
ResultBiological Significance of Isoaspartate and Its Repair System
Shimizu, T., Matsuoka, Y., & Shirasawa, T. (2005) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.28.1590 · Cited by 198
Güntert, A., Döbeli, H., & Bohrmann, B. (2006) · Neuroscience · doi:10.1016/j.neuroscience.2006.08.027 · Cited by 181
Aβ Oligomer-Induced Synapse Degeneration in Alzheimer’s Disease
Wilcox, K. C., Lacor, P. N., Pitt, J. E., & Klein, W. L. (2011) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-011-9691-4 · Cited by 178
Wirths, O., Breyhan, H., Cynis, H., Schilling, S., Demuth, H.-U., & Bayer, T. A. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0557-5 · Cited by 174 · cited 2×
“2 models [1, 68], expresses Aβ3Q-42 starting with an N-terminal glutamine (Q) residue at position three of Aβ.”
BackgroundSelf-citationBrouillette, J., Caillierez, R., Zommer, N., Alves-Pires, C., Benilova, I., Blum, D., De Strooper, B., & Buee, L. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.5901-11.2012 · Cited by 170
Lewis, H. D., Beher, D., Cookson, N., Oakley, A. E., Piggott, M. A., Morris, C. M., Jaros, E., Perry, R., Ince, P. G., Kenny, R. A., et al. (2006) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2006.00696.x · Cited by 169
Presenilin-1 mutations in Alzheimer's disease
Russo, C., Schettini, G., Saido, T. C., Hulette, C., Lippa, C., Lannfelt, L., Ghetti, B., Gambetti, P., Tabaton, M., & Teller, J. K. (2000) · Nature · doi:10.1038/35014735 · Cited by 158
Tomiyama, T., Asano, S., Furiya, Y., Shirasawa, T., Endo, N., & Mori, H. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)34045-0 · Cited by 154
Christensen, D. Z., Kraus, S. L., Flohr, A., Cotel, M.-C., Wirths, O., & Bayer, T. A. (2008) · Acta Neuropathologica · doi:10.1007/s00401-008-0451-6 · Cited by 126 · cited 1×
“For example, APP/PS1KI mice exhibit neuron loss in the CA1 region of the hippocampus [4, 7], the frontal cortex [8], and in distinct cholinergic nuclei [9].”
BackgroundSelf-citationHeterogeneity of water‐soluble amyloid β‐peptide in Alzheimer's disease and Down's syndrome brains
Russo, C., Saido, T. C., DeBusk, L. M., Tabaton, M., Gambetti, P., & Teller, J. K. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)00564-4 · Cited by 123
Kuo, Y.-M., Webster, S., Emmerling, M. R., De Lima, N., & Roher, A. E. (1998) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/s0925-4439(98)00014-3 · Cited by 122 · cited 1×
“In addition, biochemical studies showed that Aβ peptides isolated from AD brains were post-translationally modified by isomerization and racemization [26, 38].”
BackgroundPillot, T., Drouet, B., Queillé, S., Labeur, C., Vandekerckhove, J., Rosseneu, M., Pinçon‐Raymond, M., & Chambaz, J. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0731626.x · Cited by 120
Self-citationPyroglutamate Abeta pathology in APP/PS1KI mice, sporadic and familial Alzheimer’s disease cases
Wirths, O., Bethge, T., Marcello, A., Harmeier, A., Jawhar, S., Lucassen, P. J., Multhaup, G., Brody, D. L., Esparza, T., Ingelsson, M., et al. (2010) · Journal of Neural Transmission · doi:10.1007/s00702-009-0314-x · Cited by 106 · cited 1×
“Neuron loss and an associated severe neurological phenotype were found in a transgenic mouse model expressing only N-truncated Aβpe3-42 [69], supporting the concept that N-truncated Aβ is neurotoxic.”
BackgroundSelf-citationN-truncated amyloid-β oligomers induce learning impairment and neuronal apoptosis
Youssef, I., Florent‐Béchard, S., Malaplate, C., Koziel, V., Bihain, B. E., Olivier, J. L., Leininger‐Muller, B., Kriem, B., Oster, T., & Pillot, T. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.03.005 · Cited by 105
Self-citationAlexandru, A., Jagla, W., Graubner, S., Becker, A., Bäuscher, C., Kohlmann, S., Sedlmeier, R., Raber, K. A., Cynis, H., Rönicke, R., et al. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.1794-11.2011 · Cited by 102
Kumar, S., Wirths, O., Theil, S., Gerth, J., Bayer, T. A., & Walter, J. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1107-8 · Cited by 99
Self-citationShin, R.-W., Ogino, K., Kondo, A., Saido, T. C., Trojanowski, J. Q., Kitamoto, T., & Tateishi, J. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-21-08187.1997 · Cited by 97
Wittnam, J. L., Portelius, E., Zetterberg, H., Gustavsson, M. K., Schilling, S., Koch, B. C. P., Demuth, H., Blennow, K., Wirths, O., & Bayer, T. A. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.308601 · Cited by 97
Self-citationRole of Amyloid- Glycine 33 in Oligomerization, Toxicity, and Neuronal Plasticity
Harmeier, A., Wozny, C., Rost, B. R., Munter, L.-M., Hua, H., Georgiev, O., Beyermann, M., Hildebrand, P. W., Weise, C., Schaffner, W., et al. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.1336-09.2009 · Cited by 95
Inhibition of glutaminyl cyclase alters pyroglutamate formation in mammalian cells
Cynis, H., Schilling, S., Bodnár, M., Hoffmann, T., Heiser, U. F., Saido, T. C., & Demuth, H. (2006) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2006.08.003 · Cited by 90
APP/PS1KI bigenic mice develop early synaptic deficits and hippocampus atrophy
Breyhan, H., Wirths, O., Duan, K., Marcello, A., Rettig, J., & Bayer, T. A. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0539-7 · Cited by 87 · cited 1×
“For example, APP/PS1KI mice exhibit neuron loss in the CA1 region of the hippocampus [4, 7], the frontal cortex [8], and in distinct cholinergic nuclei [9].”
BackgroundSelf-citationSchlenzig, D., Rönicke, R., Cynis, H., Ludwig, H., Scheel, E., Reymann, K. G., Saido, T. C., Hause, G., Schilling, S., & Demuth, H. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2012.07707.x · Cited by 83
Quantification of Modified Amyloid β Peptides in Alzheimer Disease and Down Syndrome Brains
Hosoda, R., Saido, T. C., Otvos, L., Arai, T., Mann, D. M. A., Lee, V. M.-Y., Trojanowski, J. Q., & Iwatsubo, T. (1998) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199811000-00012 · Cited by 79
Christensen, D. Z., Bayer, T. A., & Wirths, O. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.07.022 · Cited by 77
Self-citationStructural Basis of β‐Amyloid‐Dependent Synaptic Dysfunctions
Haupt, C., Leppert, J., Rönicke, R., Meinhardt, J., Yadav, J. K., Ramachandran, R., Ohlenschläger, O., Reymann, K. G., Görlach, M., & Fändrich, M. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201105638 · Cited by 62
Phosphorylation of amyloid-β at the serine 26 residue by human cdc2 kinase
Milton, N. G. N. (2001) · Neuroreport · doi:10.1097/00001756-200112040-00047 · Cited by 59
Racemization: Its Biological Significance on Neuropathogenesis of Alzheimer's Disease.
MORI, H., ISHII, K., TOMIYAMA, T., FURIYA, Y., SAHARA, N., ASANO, S., ENDO, N., SHIRASAWA, T., & TAKIO, K. (1994) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.174.251 · Cited by 56
(1999) · doi:10.1002/1531-8249(199912)46:6<860::aid-ana8>3.0.co;2-m
Cited by
Endothelial LRP1 transports amyloid-β1–42 across the blood-brain barrier
Storck, S. E., Meister, S., Nahrath, J., Meißner, J. N., Schubert, N., Di Spiezio, A., Baches, S., Vandenbroucke, R. E., Bouter, Y., Prikulis, I., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci81108 · Cited by 477
“Next, we investigated how brain endothelial LRP1 deficiency affects AD-related behavior by examining spatial learning and memory (40, 41).”
Self-citationThe role of astrocytes in amyloid production and Alzheimer's disease
Frost, G. R., & Li, Y.-M. (2017) · Open Biology · doi:10.1098/rsob.170228 · Cited by 435
Truncated and modified amyloid-beta species
Kummer, M. P., & Heneka, M. T. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt258 · Cited by 341
Bayer, T. A., & Wirths, O. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1287-x · Cited by 165
Self-citationRichard, B. C., Kurdakova, A., Baches, S., Bayer, T. A., Weggen, S., & Wirths, O. (2015) · Journal of Alzheimer’s Disease · doi:10.3233/jad-143120 · Cited by 142
Self-citation
Metadata
- Authors
- Bouter, Y., Dietrich, K., Wittnam, J. L., Rezaei-Ghaleh, N., Pillot, T., Papot-Couturier, S., Lefebvre, T., Sprenger, F., Wirths, O., Zweckstetter, M., & Bayer, T. A.
- Affiliations
- Universitätsmedizin Göttingen (DE)
- German Center for Neurodegenerative Diseases (DE)
- Corresponding author
- Bayer, Thomas A.
- Venue
- Acta Neuropathologica
- Published
- 2013-05-18
- Volume
- 126
- Issue
- 2
- Pages
- 189-205
- ISSN
- 0001-6322 (ISSN-L)
- 1432-0533
- PMC
- PMC3722453
- OpenAlex
- W2142807222
- Cited by
- 175
- References
- 71
- Citations by year
- 2026: 9 · 2025: 7 · 2024: 8 · 2023: 11 · 2022: 16 · 2021: 22 · 2020: 16 · 2019: 16 · 2018: 14 · 2017: 12 · 2016: 13 · 2015: 17 · 2014: 12 · 2013: 2
- FWCI
- 10.19
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Acta Neuropathologica (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- MPG.PuRe (Max Planck Society) (submittedVersion, other-oa)
- GoeScholar The Publication Server of the Georg-August-Universität Göttingen (Georg-August-Universität Göttingen) (submittedVersion, cc-by)
- DZNE Pub (submittedVersion, other-oa)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, amyloid fibril formation, amyloid-beta 42, neurotoxicity, working memory deficits, spatial reference memory, transgenic mice, amyloid plaques, behavioral deficits
- MeSH terms
- Alzheimer Disease, Amyloid, Animals, Behavior, Animal, Female, Fetus, Humans, Injections, Intraventricular, Male, Mice, Inbred C57BL, Mice, Transgenic, Molecular Weight, Nerve Degeneration, Neurons, Pregnancy, Solubility, Space Perception, Amyloid beta-Peptides, Rats, Wistar, Maze Learning, Microscopy, Electron, Transmission, Mice, Rats, Primary Cell Culture
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.